BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 1980653)

  • 1. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic achlorhydria: for which diseases, when and for how long?].
    Koop H; Arnold R
    Dtsch Med Wochenschr; 1988 Mar; 113(13):516-8. PubMed ID: 2894969
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
    Piai G; Sabbatini F; Mazzacca G
    Ann Ital Chir; 1990; 61(1):11-4. PubMed ID: 1978622
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole: a new approach to gastric acid suppression.
    Buhl K; Clearfield HR
    Am Fam Physician; 1990 Apr; 41(4):1225-7. PubMed ID: 2321497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine H2-receptor antagonists and gastric acid secretion.
    Pounder RE
    Pharmacol Ther; 1984; 26(2):221-34. PubMed ID: 6152495
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a need for strong gastric acid inhibition in clinical practice?
    Lamers CB
    Digestion; 1989; 44 Suppl 1():4-8. PubMed ID: 2691309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The present state of knowledge on the treatment of peptic diseases with cimetidine].
    Romankiewicz JA; Reidenberg MM
    Internist (Berl); 1981 Dec; 22(12):762-6. PubMed ID: 6797984
    [No Abstract]   [Full Text] [Related]  

  • 15. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Powerful gastric acid inhibition: when is it justified?
    Dobrilla G; Amplatz S
    Ital J Gastroenterol; 1990; 22 Suppl 1():13-7. PubMed ID: 1983420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole and acid peptic disease.
    Piper DW; Yeomans ND; Shearman DJ
    Med J Aust; 1991 Mar; 154(6):374-5. PubMed ID: 2000048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.